Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7718776B2 · kind B2 · utility
23Cited by
87References
50Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 7, 2003 |
| Grant date | May 18, 2010 |
| Priority date | — |
| Expiry date | Apr 7, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.